STERIS plc
NYSE: STE · HEALTHCARE · MEDICAL DEVICES
Updated 2026-06-05
STERIS plc (STE) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $95.74M | $143.40M | $167.38M | $224.95M | $117.74M | $149.37M | $227.81M | $209.63M | $246.04M | $254.68M | $424.09M | $457.63M | $539.50M | $590.56M | $689.64M | $684.81M | $756.95M | $973.27M | $1.15B | $1.34B |
| Capital expenditures | $49.02M | $56.97M | $40.89M | $44.09M | $77.44M | $66.68M | $87.41M | $86.37M | $85.25M | $126.41M | $172.90M | $165.46M | $189.72M | $214.52M | $239.26M | $287.56M | $361.97M | $360.33M | $370.09M | $369.00M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $2.04M | $5.79M | $7.37M | $7.37M | $10.19M | $7.86M | $8.92M | $11.10M | $14.92M | $16.15M | $18.79M | $22.19M | $23.96M | $23.81M | $25.97M | $57.66M | $38.95M | $56.53M | $57.40M | $61.70M |
| Free cash flow | $46.72M | $86.43M | $126.50M | $180.87M | $40.30M | $82.69M | $140.40M | $123.26M | $160.78M | $128.27M | $251.19M | $292.18M | $349.79M | $376.04M | $450.38M | $397.25M | $394.98M | $612.95M | $778.00M | $972.40M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | $11.77M | $14.61M | $17.66M | $144.02M | $33.23M | $38.56M | $43.20M | $48.38M | $53.51M | $65.20M | $93.19M | $102.93M | $112.50M | $123.03M | $133.84M | $163.17M | $183.50M | $200.57M | $219.88M | $241.80M |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | $19.10M | $98.95M | $-99.05M | — | $-125.10M | — | — | — |
Frequently asked questions
What is STERIS plc's revenue?
STERIS plc's trailing twelve-month revenue is $5.94B, and consensus projects about $7.88B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is STE?
In its most recent fiscal year, STE ran a gross margin of 44.25%, an operating margin of 18.56%, and a net margin of 13.23%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does STE generate?
STE produced $972.40M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is STE's balance sheet healthy?
STE holds $439.60M in cash and equivalents against $1.81B in long-term debt, on $7.18B of shareholder equity. That debt is best read against the cash flow the business throws off each year.